A method for assisting with appetite and weight control and reduction in obese human patients, which comprises the step of orally or rectally administering an appetite-suppressant compound selected from the group consisting of femoxetine and a pharmaceutically-acceptable salt thereof in an effective appetite-suppressant amount over a period of at least eight (8) weeks is disclosed. The appetite-suppresssant compound is preferably orally administered together with a pharmaceutically-acceptable carrier in a daily dosage of 100 to 1,000 mg in the form of a tablet containing about 100 to 300 mg of the appetite-suppressant compound, which is preferably a pharmaceutically-acceptable femoxetine acid addition salt, especially the hydrochloride.
展开▼
